Chiang et al. demonstrated the beneficial effects of SGLT2 inhibitors in breast cancer patients treated with anthracyclines, with no increased risk of serious adverse events, such as hypoglycemia or sepsis [66]. Here, SLC5A2 is linked to breast cancer.